Business Context and Reporting Period
This Form 8-K, dated July 15, 2025, reports on the results of the Annual Meeting of stockholders for Ikena Oncology, Inc. (ticker: IKNA). The filing details the approval of a merger with Inmagene Biopharmaceuticals, which will result in the formation of a combined entity named ImageneBio, Inc. (ticker: IMA). The report covers corporate actions taken on July 15, 2025, including the approval of equity plans, director elections, and a reverse stock split.
Key Financial Metrics and Capital Structure
The filing does not provide specific revenue, profit, cash flow, or debt figures for the reporting period. Key capital structure metrics include:
- Shares Outstanding: 41,889,525 shares of Ikena common stock were outstanding and entitled to vote as of the May 22, 2025 record date.
- Quorum: 38,237,401 shares were represented at the Annual Meeting.
- Reverse Stock Split: A 1-for-12 reverse stock split was approved, expected to reduce outstanding shares from approximately 48.2 million to 4 million (excluding merger issuance).
- Equity Reserve: The approved 2025 Equity Incentive Plan will initially reserve 10% of the Combined Company's outstanding capital stock, plus shares from terminated awards under the 2021 plan.
- ESPP Reserve: The 2025 Employee Stock Purchase Plan will reserve 1% of the Combined Company's outstanding capital stock.
Material Changes and Corporate Actions
Significant corporate changes approved by stockholders include:
- Merger Approval: Stockholders approved the issuance of shares to Inmagene securityholders and concurrent financing investors, representing a change of control. The merger is expected to close around the end of July 2025.
- Reverse Stock Split: The board approved a 1-for-12 reverse stock split to be effected prior to the merger closing. Fractional shares will be settled in cash.
- Rebranding: Post-merger, the combined company will trade under the name "ImageneBio, Inc." with the ticker symbol "IMA" and a new CUSIP number (45175G 207).
- Accounting Firm: Stockholders ratified Ernst & Young LLP for the 2025 fiscal year, with a provision that PricewaterhouseCoopers LLP will be appointed if the merger is completed.
Guidance, Outlook, and Risks
Outlook and Timing: The merger and concurrent financing are expected to be consummated around the end of July 2025, subject to closing conditions. The combined company's stock is expected to commence trading on Nasdaq on a split-adjusted basis immediately following the merger.
Risks and Contingencies: The filing highlights several material risks, including:
- Failure to satisfy conditions for the merger closing or termination of the Merger Agreement.
- Uncertainty regarding the timing of the reverse stock split and merger consummation.
- Risks associated with the clinical development and regulatory approval of product candidates (e.g., IMG-007).
- Potential inability to secure sufficient additional capital for future operations.
- Uncertainty regarding the realization of anticipated benefits from the merger.
Investor Verification Checklist
- Verify the final closing date of the merger and the concurrent financing.
- Confirm the effective date of the 1-for-12 reverse stock split and the cash settlement process for fractional shares.
- Monitor the transition of the ticker symbol from IKNA to IMA and the assignment of the new CUSIP.
- Review the definitive terms of the 2025 Equity Incentive Plan and ESPP for dilution impact on the combined entity.
- Check for any updates on the appointment of PricewaterhouseCoopers LLP as the independent auditor post-merger.